Oxford Asset Management’s Sage Therapeutics SAGE Stock Holding History

Oxford Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,701	Closed	-$940K	–	2039
2019 Q3	$940K	Buy	+6,701	New	+$1.12M	0.02%	978
2018 Q4	–	Sell	-15,251	Closed	-$2.13M	–	2060
2018 Q3	$2.13M	Buy	+15,251	New	+$2.35M	0.04%	630
2018 Q1	–	Sell	-5,805	Closed	-$965K	–	1855
2017 Q4	$965K	Buy	+5,805	New	+$563K	0.02%	955
2017 Q2	–	Sell	-14,014	Closed	-$996K	–	1673
2017 Q1	$996K	Sell	14,014 -31,590	-69%	-$1.85M	0.02%	807
2016 Q4	$2.33M	Buy	45,604 +8,156	+22%	+$384K	0.08%	283
2016 Q3	$1.72M	Sell	37,448 -135,037	-78%	-$5.5M	0.05%	427
2016 Q2	$5.2M	Buy	+172,485	New	+$5.75M	0.17%	138
2016 Q1	–	Sell	-115,936	Closed	-$6.75M	–	884
2015 Q4	$6.75M	Buy	+115,936	New	+$5.74M	0.16%	134

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Oxford Asset Management's SAGE Position: Q4 2019 in Review

Oxford Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 6,701 shares — an estimated $940K sold.

Oxford Asset Management first reported a position in SAGE in Q4 2015 and held it in 8 quarters. The position peaked at $6.75M in Q4 2015. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

Oxford Asset Management reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
Oxford Asset Management sold 6,701 Sage Therapeutics shares in Q4 2019, an estimated $940K.
Oxford Asset Management first reported a position in Sage Therapeutics in Q4 2015 and held it in 8 quarters.
Oxford Asset Management's Sage Therapeutics position peaked at $6.75M in Q4 2015.
266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Oxford Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.